Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells
- PMID: 16459188
- DOI: 10.1016/j.exphem.2005.11.004
Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells
Abstract
Objective: Several studies have demonstrated that dendritic cells (DCs) pulsed with tumor lysate or apoptotic tumor cells can elicit effective T-cell responses. This technique does not require the identification of the tumor antigen or HLA haplotype of the patient. We applied this approach to induce HLA class I- and class II-restricted T-cell responses directed against autologous acute lymphocytic leukemia (B-ALL) cell line NH-1.
Methods: Autologous T cells were stimulated by apoptotic tumor cell-loaded DCs generated from a patient with ALL. The stimulated and expanded T cells were isolated into CD8(+) T-cell line and CD4(+) T-cell line, and each of them was examined as to their functions.
Results: Both CD8(+) and CD4(+) T-cell lines demonstrated cytotoxicity against NH-1 in an major histocompatibility complex-dependent manner. Finally, we established two independent CD4(+) T-cell clones restricted to HLA-DR. The CD4(+) T-cell line responded strongly to autologous Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) but not to autologous normal cells. Furthermore, the T-cell clones also responded to allogeneic EBV-LCLs and B-ALL cell lines in the context of the HLA-DRB1( *)04051 molecule. Interestingly, 293T and COS-7 cells, which had been transfected with the HLA-DRB1( *)04051, were also recognized by T-cell clones.
Conclusion: These findings indicate that B-ALL has shared and strong immunogenic epitopes expressed on HLA class II molecules, the expression of which is limited to immortalized cells. These data suggest that vaccinations using DCs loaded with apoptotic tumor cells might be a potent strategy in the treatment of B-ALL.
Similar articles
-
Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.Clin Cancer Res. 2005 May 1;11(9):3446-54. doi: 10.1158/1078-0432.CCR-04-2043. Clin Cancer Res. 2005. PMID: 15867247
-
Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.Clin Cancer Res. 2005 Nov 1;11(21):7891-900. doi: 10.1158/1078-0432.CCR-05-1330. Clin Cancer Res. 2005. PMID: 16278414
-
In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.Clin Cancer Res. 2006 Mar 15;12(6):1921-7. doi: 10.1158/1078-0432.CCR-05-1900. Clin Cancer Res. 2006. PMID: 16551878
-
Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.Gynecol Oncol. 2005 Nov;99(2):462-71. doi: 10.1016/j.ygyno.2005.07.019. Epub 2005 Aug 30. Gynecol Oncol. 2005. PMID: 16137749 Review.
-
Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.J Gene Med. 2005 Jun;7(6):686-95. doi: 10.1002/jgm.713. J Gene Med. 2005. PMID: 15693037 Review.
Cited by
-
Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.J Cancer Res Clin Oncol. 2008 May;134(5):525-33. doi: 10.1007/s00432-007-0315-9. Epub 2007 Oct 2. J Cancer Res Clin Oncol. 2008. PMID: 17909857 Free PMC article.
-
T cell exhaustion in pediatric B-ALL: current knowledge and future perspectives.Front Immunol. 2025 May 28;16:1531145. doi: 10.3389/fimmu.2025.1531145. eCollection 2025. Front Immunol. 2025. PMID: 40503229 Free PMC article. Review.
-
Effect of Wuye Decoction on lymphocyte phenotype in patients with non-small cell lung cancer.Chin J Integr Med. 2006 Jun;12(2):118-21. doi: 10.1007/BF02857357. Chin J Integr Med. 2006. PMID: 16800990 Clinical Trial.
-
Can Dendritic Cell Vaccination Prevent Leukemia Relapse?Cancers (Basel). 2019 Jun 22;11(6):875. doi: 10.3390/cancers11060875. Cancers (Basel). 2019. PMID: 31234526 Free PMC article. Review.
-
Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.Front Immunol. 2024 Jan 17;14:1325255. doi: 10.3389/fimmu.2023.1325255. eCollection 2023. Front Immunol. 2024. PMID: 38299154 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials